Docstoc

Method For Exfoliating Skin - Patent 7514070

Document Sample
Method For Exfoliating Skin - Patent 7514070 Powered By Docstoc
					


United States Patent: 7514070


































 
( 1 of 1 )



	United States Patent 
	7,514,070



 Basara
 

 
April 7, 2009




Method for exfoliating skin



Abstract

The present invention relates to an exfoliating composition. The
     composition comprises a mixture. The mixture comprises phenolsulfonic
     acid, guaiacolsulfonic acid, and optionally sulfosalicylic acid and
     citric acid.


 
Inventors: 
 Basara; Michael (Hugo, MN) 
 Assignee:


EPIEN Medical, Inc.
 (White Bear Lake, 
MN)





Appl. No.:
                    
11/457,353
  
Filed:
                      
  July 13, 2006

 Related U.S. Patent Documents   
 

Application NumberFiling DatePatent NumberIssue Date
 10443445Nov., 20047115251
 

 



  
Current U.S. Class:
  424/47  ; 424/400; 424/70.8
  
Current International Class: 
  A61K 9/00&nbsp(20060101)
  
Field of Search: 
  
  











 424/400,401,434,47,70.1,43,59,70.8,70.24,78.02,78.03,78.08
  

References Cited  [Referenced By]
U.S. Patent Documents
 
 
 
3459800
August 1969
Salat et al.

3920835
November 1975
Van Scott et al.

3984556
October 1976
Hardtmann

3988470
October 1976
Van Scott et al.

4080212
March 1978
Takahashi

4082841
April 1978
Pader

4144325
March 1979
Voyt

4416982
November 1983
Tsuda et al.

5688995
November 1997
Luther et al.

6596299
July 2003
Basara

6830757
December 2004
Basara

7115251
October 2006
Basara

7132111
November 2006
Basara

2004/0234490
November 2004
Basara



 Foreign Patent Documents
 
 
 
820659
Sep., 1959
GB

WO-2004062580
Jul., 2004
WO



   
 Other References 

Budavari, et al., The Merck Index, eleventh edition, (1989),7212. cited by other
.
Forstner, J. , et al., "Intestinal goblet cell mucus: isolation and identification by immunofluorescence of a goblet cell glycoprotein", J Cell Sci., 12(2), (Mar. 1973),585-602. cited by other
.
Lebat-Robert, J. , et al., "Glycoproteines du mucus gastrique: structure, fonctions et pathologie", Pathologie biologle, 24, (1979),241-247. cited by other
.
Lehr, C. M., et al., "Visualization studies of the mucoadhesive interface", Journal of Controlled Release, 18, (1992),249-260. cited by other
.
Peppas, N. , et al., "Suface, interfacial and molecular aspects of polymer bioadhesion on soft tissues", Journal of Controlled Release, 2, (1985),257-275. cited by other
.
Spiro, R. G., "Glycoproteins", Annu Rev Biochem., 39, (1970),599-638. cited by other.  
  Primary Examiner: Jones; D. L


  Attorney, Agent or Firm: Schwegman, Lundberg & Woessner, P.A.



Parent Case Text



RELATED APPLICATIONS


This application is a continuation of U.S. patent application Ser. No.
     10/443,445, filed May 21, 2003, Issued on Nov. 25, 2004 as U.S. Pat. No.
     7,115,251. Reference is made to the following commonly assigned
     application entitled as follows: ODORLESS FORMULATION FOR TREATING
     MUCOSAL DISCONTINUITIES. The above-identified application being filed on
     May 21, 2003, Ser. No. 10/443,446, the same filing date as U.S. patent
     application Ser. No. 10/443,445 and Issued on Nov. 7, 2006 as U.S. Pat.
     No. 7,132,111.

Claims  

What is claimed is:

 1.  A method for making a skin exfoliant usable by a consumer, comprising: preparing an exfoliating composition comprising isomers of phenolsulfonic acid, and isomers of
guaiacolsulfonic acid and, optionally, sulfosalicylic acid;  and adding water or alcohol or a mixture of water and alcohol as a diluent to the exfoliating composition.


 2.  The method of claim 1, further comprising adding citric acid.


 3.  The method of claim 1, further comprising adding one or both of ammonium phenolsulfonate and zinc phenolsulfonate.


 4.  The method of claim 1, further comprising adding sulfosalicylic acid.


 5.  The method of claim 1, further comprising adding an emulsifier selected from the group consisting of glyceryl stearate and laureth 23, PEG 20 stearate, and mink-amidopropyl dimethy 2-hydroxyethylammonium chloride.


 6.  The method of claim 1, further comprising applying the skin exfoliant.


 7.  The method of claim 1, wherein the exfoliating composition is a cream or paste.


 8.  The method of claim 1, wherein the exfoliating composition is a gel.


 9.  The method of claim 1, wherein the exfoliating composition further comprises an emulsifier.


 10.  The method of claim 1, wherein the exfoliating composition further comprises a preservative.


 11.  The method of claim 1, wherein the exfoliating composition further comprises an emollient.  Description  

BACKGROUND OF THE INVENTION


The present invention relates to a method for exfoliating skin, including facial skin, skin on the bottom of feet, and elbows.


Skin atrophy refers to a thinning or general degradation of the dermis layer of mammalian skin.  Skin atrophy is often characterized by a decrease in collagen and elastin.  Skin atrophy is a natural result of aging, but may be caused by either
intrinsic or extrinsic factors such as natural chronological aging, photo damage, burns or chemical damage, or by exposure to pollutants or allergens such as cigarette smoke.  Skin atrophy is an undesirable side effect resulting from treatment with alpha
hydroxy carboxylic acids.


On the opposite end of the spectrum are corns and callouses.  Corns and callouses are hard skin that develops when skin is exposed to excessive pressure or friction.  A corn is hard skin with a small core that includes tissue that is as hard as
bone or nail.  Corns and callouses are typically treated with abrasive materials and abrasive devices.


Cosmetic compositions that include alpha or beta hydroxy acid, AHA/BHA as the active ingredient, are well-known in the art.  These compositions are useful in improving skin tone, reduction of fine lines, enhancement of moisture, and development
of smooth skin.  Application of AHA/BHA results in younger looking skin as new cells replace the old.  Unfortunately, the AHA/BHA acts most effectively at low pH conditions.  In order to improve skin condition, users must tolerate skin irritation caused
by the acid present in the AHA/BHA products.  Skin irritation is a major concern then, to manufacturers and users to these products.


SUMMARY OF THE INVENTION


One embodiment of the present invention is an exfoliating composition.  The exfoliating composition comprises a mixture comprising phenolsulfonic acid, guaiacolsulfonic acid and, optionally, sulfosalicylic acid.


Another embodiment of the present invention includes a method for exfoliating skin, comprising: cleansing skin that is to be exfoliated; providing an exfoliating composition comprising phenolsulfonic acid, guaiacolsulfonic acid and, optionally,
sulfosalicylic acid; and applying the exfoliating composition to skin which has been cleansed for a time effective to exfoliate the skin.


Another embodiment of the present invention includes a method for making an exfoliant, comprising: blending a mixture of one or more phenolsulfonic acid, guaiacolsulfonic acid, sulfosalicylic acid, and citric acid in amounts effective to
exfoliate skin.


One other embodiment of the present invention includes a device comprising: the formulation of the present invention and a container for enclosing and transporting the formulation. 

DETAILED DESCRIPTION


One embodiment of the present invention includes a method for exfoliating skin.  The method comprises exposing skin, which has been cleansed, to a solution or a cream or lotion or paste or gel or foam comprising one or more of sulphonated
phenolic compounds including phenolsulfonic acid, guaiacolsulfonic acid, and sulfosalicylic acid, for a time effective to warm the skin and produce a tingling sensation.  The solution or cream or paste or gel or foam comprises a mixture of phenolsulfonic
acid and one or more of guaiacolsulfonic acid and sulfosalicylic acid.  Some embodiments optionally include free acid.  In one embodiment, the mixture includes:


 TABLE-US-00001 Component Concentration Ranges Phenolsulfonic Acid 25-80% by weight Guaiacolsulfonic Acid 25-80% by weight Ammonium Phenolsulfonate 0-5% by weight Free Sulfuric Acid 0-3% by weight Water 13-30% by weight Colorant 0.075-0.020% by
weight


One exfoliant of the present invention includes two isomers of phenolsulfonic acid and four isomers of guaiacolsulfonic acid.  Water is added as a diluent in this formulation.  Another exfoliant of the present invention additionally includes
sulfosalicylic acid.  One other exfoliant embodiment includes citric acid.  An embodiment used as a foot exfoliant includes ammonium phenolsulfonate and zinc phenolsulfonate.  These embodiments include water or alcohol or a mixture of water and alcohol
as a diluent.


It is believed that the exfoliant formulations of the present invention macerate the stratus corneum without penetrating into the underlying skin tissue.  The exfoliant produces a precipitation reaction that cleanses the skin, particularly
lesions on the surface of the skin, without damaging underlying layers.  The cleansing aids in repair of the lesions and in the growth of new skin.


One specific embodiment of the solution has the following concentration ranges:


 TABLE-US-00002 Component Concentration Ranges Phenolsulfonic Acid 25-80% by weight Guaiacolsulfonic Acid 25-80% by weight Ammonium Phenolsulfonate 0-32% by weight Free Sulfuric Acid 0-32% by weight Water 13-30% by weight Colorant 0.000-0.075% by
weight


Another formulation embodiment is as follows:


 TABLE-US-00003 Component Concentration Ranges Phenolsulfonic Acid 25-80% by weight Guaiacolsulfonic Acid 25-80% by weight Ammonium Phenolsulfonate 0-5% by weight Free Sulfuric Acid 0-3% by weight Water 13-30% by weight Colorant 0.000-0.075% by
weight


As used herein, "Exfoliation" refers to a detachment and shedding of superficial cells of an epithelium or from any tissue surface.  Tissue surfaces include but are not limited to facial skin, skin on the soles of feet, knees, elbows, legs, arms,
and other skin areas.  Exfoliation also includes detachment or shedding of calloused skin, such as skin on the sole and heel of a foot, skin on an elbow and callouses on other parts of the body.


"Pharmaceutical" refers to a formulation administered to the skin which renders a benefit or an effect for treating or preventing an abnormal biological condition or a disease.


"Skin Atrophy" refers to a thinning and/or a general degradation of the dermis layer of mammalian skin, often characterized by a degree in collagen and/or elastic, as well as a doubling of fibroblast cells.  Skin atrophy is a natural result of
the aging process, but may be caused by either intrinsic or extrinsic factors such as photo damage, bums or chemical damage, or by exposure to pollutants or allergens such as cigarette smoke.  Skin atrophy is often an undesirable side-effect resulting
from treatment with alpha hydroxy carboxylic acids.


One embodiment of the present invention includes an exfoliation composition.  The exfoliation composition of the present invention includes creams, gels, foams and pastes.  The formulation includes a diluent such as water, aqueous alcohol, glycol
or other inactive carrier which includes up to about 4 percent sulfonated phenol exfoliating material.  The exfoliation material, intended for topical application includes, for some embodiments, carrier, excipient, or vehicle ingredients such as, for
example, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3 diol, isopropyl myristate, isopropyl palmitate, mineral oil and mixtures thereof to form lotions, tinctures, creams, emulsions, gels, or ointments which are non-toxic and
pharmaceutically, cosmetically or dermatologically acceptable.  Additionally, moisturizers or humectants are added to the present composition, if desired.


In addition to the diluent, formulations of the sulfonated phenols also, for some embodiments, include other standard adjuvants such as an emollient, moisturizer, thickener, emulsifier, neutralizer, coloring agent, UV absorber or filter,
preservative and or gelling agent.  When employed in a formulation, these adjutants are present in amounts ranging from about 0.5% to 30%.


Emollient


Acceptable emollients include saturated fatty acids such as isopropyl myristate, cetyl palmitate and octyldodecylmyristate, beeswax, saturated and unsaturated fatty alcohols such as behenyl alcohol and cetyl alcohol, hydrocarbons such as mineral
oils, petrolatum, squalene, fatty sorbitan esters, lanolin and lanolin derivatives, such as lanolin alcohol ethoxylated, hydroxylated and acetylated lanolins, cholesterol and derivatives thereof, animal and vegetable triglycerides such as almond oil,
peanut oil, wheat germ oil, linseed oil, jojoba oil, oil of apricot pits, walnuts, palm nuts, pistachio nuts, sesame seeds, rapeseed, cade oil, corn oil, peach pit oil, poppyseed oil, pine oil, castor oil, soybean oil, avocado oil, safflower oil, coconut
oil, hazelnut oil, olive oil, grapeseed oil, and sunflower seed oil and diisostearylmalate, diisostearyldimerate and triisostearyltrimerate.


Suitable emollients for use herein include isocetyl alcohol, octyl palmitate, isostearyl neopentanoate and isocetyl stearyl stearate, natural or synthetic oils selected from mineral, vegetable, and animal oils, fats and waxes, fatty acid esters,
fatty alcohols, alkylene glycol and polyalkylene glycol ethers and esters, fatty acids and mixtures thereof.


Emulsifier


Suitable emulsifiers include glyceryl stearate and laureth 23, PEG 20 stearate, and mink-amidopropyl dimethyl 2-hydroxyethylammonium chloride.


Typical moisturizers used in the formulation of the present invention include glycerin, petrolatum and maleated vegetable oil.


The sulphonated phenolic material is formulated, in some embodiments, with a gelling agent.  Suitable gelling agents include water soluble or colloidally water soluble polymers and include cellulose ethers, such as hydroxyethyl cellulose, methyl
cellulose, hydroxypropylmethyl cellulose, polyvinylalcohol, polyquaternium-10, guar gum, hydroxypropyl guar gum and xanthan gum.  Other gelling agents usable the present invention include acrylic acid/ethyl acrylate copolymers and carboxyvinyl polymers. 
Also usable are maleic anhydride-alkyl methylvinylethers and copolymers, natural gums, and polymethacrylate copolymer.  Other suitable gelling agents include oleogels such as trihydroxystearin and aluminum magnesium hydroxy stearate.


Some embodiments of the formulation of the present invention include preservatives.  The preservatives include sodium benzoate and propyl paraben and mixtures of these materials.  Other additional materials include fragrances, fillers such as
nylon, sun screens, electrolytes such as sodium chloride, proteins, antioxidants and chelating agents, and ultraviolet absorbing agents.  The ultraviolet absorbing agents include benzophenone-3, benzophenone-4, oxytyl dimethyl PABA (Padimate O), octyl
methoxy cinnamate, octyl salicylate, octocrylene, p-methylbenzylidene camphor, butyl methoxy dibenzoyl methane, titanium dioxide, zinc oxide and mixtures of these materials.


The exfoliant compositions of the present invention are believed to enhance cell renewal, skin smoothing, exfoliation of calloused skins, removal of skin blemishes, reduction in corn size, and in toning skin.


In addition to these and other vehicles which are selected by those being skilled in the art, it is understood that pharmaceutical and cosmetic compositions of the present invention include other ingredients such as, for example, not by way of
limitation, those that improve or eradicate age spots, keratosis and wrinkles; analgesics; anaesthetics; anti-acne agents; anti-bacterial, anti-yeast agents, anti-fungal agents, anti-viral agents, anti-dandruff agents, anti-dermatitis agents,
anti-pruritic agents, anti-metic agents, anti-inflammatory agents, anti-hyperkeratolytic agents, anti-dry skin agents, anti-perspirants, anti-psoriatic agents, anti-seborrheic agents, hair conditioners and hair treatment agents, anti-aging and
anti-wrinkle agents, skin-whitening agents, de-pigmenting agents, vitamins, tanning agents, hormones, retinoids, vitamin A palmitate and vitamin E acetate.


The present invention also includes methods for enhancing epidermal exfoliation and/or enhancing epidermal skin renewal.  The method includes topically administering to an area of a subject's skin, an effective amount of a composition of the
present invention for a period of time effective to enhance epidermal exfoliation and /or enhance epidermal skin renewal.


The present invention also provides methods for improving the texture and/or appearance of skin.  The method comprises administering to an area of a subject's skin, an effective amount of the exfoliant of the present invention for a period of
time effective to improve the texture and/or appearance of skin.  In one embodiment, the application time is within a range of thirty seconds to thirty minutes.


The present invention also provides methods for treating or preventing an abnormal skin condition, disease or disorder.  The methods comprise administering to an area of a subject's skin an effective amount of the exfoliant of the present
invention which comprises two isomers of phenolsulfonic acid, four isomers of guaiacolsulfonic acid and, optionally, sulfosalicylic acid for a period of time effective to treat or prevent an abnormal skin condition, disease, or disorder.  The time range
is thirty seconds to thirty minutes.


The condition, disease or disorder includes, but is not limited to, dry skin, severe dry skin, dandruff, acne, keratosis, eczema, skin flakiness, age spots, hyper-pigmented skin, inflammatory dermatosis, age-related skin changes, skin in need of
cleansers, and the effects of skin atrophy and psoriasis.


One method of administration of an effective amount of the exfoliant of the present invention for any of the methods described herein is when on an area of skin by a topical application.  The amount of the exfoliant and frequency of topical
application to the skin varies widely, depending upon factors such as the particular skin disorder, the severity of the skin disorder, the location and/or type of skin involved, the subject's skin sensitivity, and the degree of treatment desired.  It is
well within the purview of the skilled artisan to administer regular dosages according to a subject's need.  It is suggested as an example that daily application range from about once per week to about one time per day.


Another mode of administration is a chronic administration.  Chronic administration has a duration of months to years.  Chronic administration also ranges from about once per week to once per day.


A kit embodiment for treatment of callouses on feet or other body part, includes the exfoliation formulation of the present invention, a container for the formulation and a device for abraiding a callous after the exfoliation formulation is
applied.  The device includes one or more of an abrasive pad, a brush, an abrasive board, or other abrasive device.


Some embodiments of the exfoliant are applied in spas, salons, or other facilities specializing in skin care.  Other embodiments are applied in the home by a purchaser.  Some embodiments of the exfoliant are sold in drug stores, grocery stores,
and department stores.


While specified embodiments of the invention have been herein described, it is to be appreciated that various changes, rearrangements and modifications may be made therein without departing from the scope of the invention as defined by the
appended claims.


* * * * *























				
DOCUMENT INFO
Description: The present invention relates to a method for exfoliating skin, including facial skin, skin on the bottom of feet, and elbows.Skin atrophy refers to a thinning or general degradation of the dermis layer of mammalian skin. Skin atrophy is often characterized by a decrease in collagen and elastin. Skin atrophy is a natural result of aging, but may be caused by eitherintrinsic or extrinsic factors such as natural chronological aging, photo damage, burns or chemical damage, or by exposure to pollutants or allergens such as cigarette smoke. Skin atrophy is an undesirable side effect resulting from treatment with alphahydroxy carboxylic acids.On the opposite end of the spectrum are corns and callouses. Corns and callouses are hard skin that develops when skin is exposed to excessive pressure or friction. A corn is hard skin with a small core that includes tissue that is as hard asbone or nail. Corns and callouses are typically treated with abrasive materials and abrasive devices.Cosmetic compositions that include alpha or beta hydroxy acid, AHA/BHA as the active ingredient, are well-known in the art. These compositions are useful in improving skin tone, reduction of fine lines, enhancement of moisture, and developmentof smooth skin. Application of AHA/BHA results in younger looking skin as new cells replace the old. Unfortunately, the AHA/BHA acts most effectively at low pH conditions. In order to improve skin condition, users must tolerate skin irritation causedby the acid present in the AHA/BHA products. Skin irritation is a major concern then, to manufacturers and users to these products.SUMMARY OF THE INVENTIONOne embodiment of the present invention is an exfoliating composition. The exfoliating composition comprises a mixture comprising phenolsulfonic acid, guaiacolsulfonic acid and, optionally, sulfosalicylic acid.Another embodiment of the present invention includes a method for exfoliating skin, comprising: cleansing skin that is to be exfoliated; provi